The active ingredient in Wegovy (semaglutide) mimics the GLP-1 hormone that is naturally produced in the body, increasing feelings of fullness and slowing down the rate at which food leaves the stomach
In our study using June 2024 data on fee-for-service Medicaid in 50 states and Washington, D.C., only 13 covered GLP-1s for weight loss in adults
Orals: Metsera candidates + YP05002 Two distinct oral GLP-1 families now in development some overlap risk, but Pfizer can segment by tolerability, dosing, and combination potential
Theres a pretty high percentage of people that when you give them these medications, they just really have no effect from them no real change in appetite and no meaningful weight loss, he says
So while diet and supplements may support normal GLP-1 signaling, they dont replicate the sustained effect of medication